Feb 23, 2023 / 11:00AM GMT
Susan Ringdal - Hikma Pharmaceuticals PLC - EVP of Strategic Planning & Global Affairs
Good morning, everyone, and thank you for joining Hikma's results Q&A today. Hopefully, you have all been able to download our prerecorded presentation from hikma.com. I'm very pleased to have our Hikma management team here with us today. We're joined by our CEO, Said Darwazah; our CFO, Khalid Nabilsi; Vice Chairman of Hikma and Head of the Branded business, Mazen Darwazah; the President of Injectables, Riad Mishlawi; and the President of Generics, Brian Hoffmann.
With no further ado, I will pass the call over to Said.
Khalid Waleed Hosny Al Nabilsi - Hikma Pharmaceuticals PLC - CFO
Thank you, Susan, and good morning, everybody. I'm sure you've already -- or I hope you've already read the releases. I'm extremely happy with the results this year. In a very relatively tough year, we have delivered resilient results. Our top line is almost the same as last year, and the core operating profit is down about 6%. And when you consider the extra interest rates that we
Full Year 2022 Hikma Pharmaceuticals PLC Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot